MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 319782 | Name: Anagliptin
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Anagliptin, also known as SK-0403, is a potent DPP-4 Inhibitor for the treatment of type 2 diabetes mellitus. It is approved for use in Japan in 2012. The use of anagliptin in patients with type 2 diabetes is considered to be safe and effective for both monotherapy and combination therapy.

Chemical Structure

Anagliptin
Anagliptin
CAS#739366-20-2

Theoretical Analysis

MedKoo Cat#: 319782

Name: Anagliptin

CAS#: 739366-20-2

Chemical Formula: C19H25N7O2

Exact Mass: 383.2070

Molecular Weight: 383.46

Elemental Analysis: C, 59.51; H, 6.57; N, 25.57; O, 8.34

Price and Availability

Size Price Availability Quantity
10mg USD 465.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
SK-0403; SK 0403; SK0403; Anagliptin. trade name Suiny.
IUPAC/Chemical Name
(S)-N-(2-((2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)amino)-2-methylpropyl)-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide
InChi Key
LDXYBEHACFJIEL-HNNXBMFYSA-N
InChi Code
InChI=1S/C19H25N7O2/c1-13-7-16-21-9-14(11-26(16)24-13)18(28)22-12-19(2,3)23-10-17(27)25-6-4-5-15(25)8-20/h7,9,11,15,23H,4-6,10,12H2,1-3H3,(H,22,28)/t15-/m0/s1
SMILES Code
O=C(C1=CN2C(N=C1)=CC(C)=N2)NCC(C)(NCC(N3[C@H](C#N)CCC3)=O)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 383.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Deacon CF, Lebovitz HE. A Comparative Review of DPP-4 Inhibitors and Sulphonylureas. Diabetes Obes Metab. 2015 Nov 24. doi: 10.1111/dom.12610. [Epub ahead of print] Review. PubMed PMID: 26597596. 2: Imai C, Harazaki T, Inoue S, Mochizuki K, Goda T. Treatment with DPP-4I Anagliptin or α-GI Miglitol Reduces IGT Development and the Expression of CVD Risk Factors in OLETF Rats. J Nutr Sci Vitaminol (Tokyo). 2015;61(4):313-21. doi: 10.3177/jnsv.61.313. PubMed PMID: 26440638. 3: Fisman EZ, Tenenbaum A. Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovasc Diabetol. 2015 Sep 29;14:129. doi: 10.1186/s12933-015-0294-0. PubMed PMID: 26415691; PubMed Central PMCID: PMC4587723. 4: Chen XW, He ZX, Zhou ZW, Yang T, Zhang X, Yang YX, Duan W, Zhou SF. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015 Oct;42(10):999-1024. doi: 10.1111/1440-1681.12455. Review. PubMed PMID: 26173919. 5: Watanabe YS, Yasuda Y, Kojima Y, Okada S, Motoyama T, Takahashi R, Oka M. Anagliptin, a potent dipeptidyl peptidase IV inhibitor: its single-crystal structure and enzyme interactions. J Enzyme Inhib Med Chem. 2015 Dec;30(6):981-8. doi: 10.3109/14756366.2014.1002402. Epub 2015 Jul 6. PubMed PMID: 26147347. 6: Nakamura Y, Hasegawa H, Tsuji M, Udaka Y, Mihara M, Shimizu T, Inoue M, Goto Y, Gotoh H, Inagaki M, Oguchi K. Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors. World J Diabetes. 2015 Jun 25;6(6):840-9. doi: 10.4239/wjd.v6.i6.840. Review. PubMed PMID: 26131325; PubMed Central PMCID: PMC4478579. 7: Aoki K, Ijima T, Kamiyama H, Kamiko K, Terauchi Y. Anagliptin decreases serum lathosterol level in patients with type 2 diabetes: a pilot study. Expert Opin Pharmacother. 2015;16(12):1749-54. doi: 10.1517/14656566.2015.1057120. Epub 2015 Jun 22. PubMed PMID: 26098722. 8: Shinjo T, Nakatsu Y, Iwashita M, Sano T, Sakoda H, Ishihara H, Kushiyama A, Fujishiro M, Nishimura F, Asano T. High-fat diet feeding significantly attenuates anagliptin-induced regeneration of islets of Langerhans in streptozotocin-induced diabetic mice. Diabetol Metab Syndr. 2015 Jun 2;7:50. doi: 10.1186/s13098-015-0047-y. eCollection 2015. PubMed PMID: 26097511; PubMed Central PMCID: PMC4475295. 9: Shinjo T, Nakatsu Y, Iwashita M, Sano T, Sakoda H, Ishihara H, Kushiyama A, Fujishiro M, Fukushima T, Tsuchiya Y, Kamata H, Nishimura F, Asano T. DPP-IV inhibitor anagliptin exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-κB activation. Am J Physiol Endocrinol Metab. 2015 Aug 1;309(3):E214-23. doi: 10.1152/ajpendo.00553.2014. Epub 2015 May 26. PubMed PMID: 26015438. 10: Nishio S, Abe M, Ito H. Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability. Diabetes Metab Syndr Obes. 2015 Mar 18;8:163-71. doi: 10.2147/DMSO.S54679. eCollection 2015. Review. PubMed PMID: 25834461; PubMed Central PMCID: PMC4370682. 11: Yang HK, Min KW, Park SW, Chung CH, Park KS, Choi SH, Song KH, Kim DM, Lee MK, Sung YA, Baik SH, Kim IJ, Cha BS, Park JH, Ahn YB, Lee IK, Yoo SJ, Kim J, Park IeB, Park TS, Yoon KH. A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes. Endocr J. 2015;62(5):449-62. doi: 10.1507/endocrj.EJ14-0544. Epub 2015 Mar 27. PubMed PMID: 25819061. 12: Higashijima Y, Tanaka T, Yamaguchi J, Tanaka S, Nangaku M. Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury. Am J Physiol Renal Physiol. 2015 Apr 15;308(8):F878-87. doi: 10.1152/ajprenal.00590.2014. Epub 2015 Feb 4. PubMed PMID: 25656369. 13: Jin SM, Park SW, Yoon KH, Min KW, Song KH, Park KS, Park JY, Park IB, Chung CH, Baik SH, Choi SH, Lee HW, Lee IK, Kim DM, Lee MK. Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension. Diabetes Obes Metab. 2015 May;17(5):511-5. doi: 10.1111/dom.12429. Epub 2015 Jan 14. PubMed PMID: 25523633. 14: Kishimoto M, Noda M. Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study. Clin Drug Investig. 2015 Feb;35(2):141-7. doi: 10.1007/s40261-014-0260-8. PubMed PMID: 25511640; PubMed Central PMCID: PMC4300407. 15: Kakuda H, Kobayashi J, Kakuda M, Yamakawa J, Takekoshi N. The effect of anagliptin treatment on glucose metabolism and lipid metabolism, and oxidative stress in fasting and postprandial states using a test meal in Japanese men with type 2 diabetes. Endocrine. 2015 Apr;48(3):1005-9. doi: 10.1007/s12020-014-0376-x. Epub 2014 Aug 13. PubMed PMID: 25115636. 16: Filippatos TD, Athyros VG, Elisaf MS. The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. Expert Opin Drug Metab Toxicol. 2014 Jun;10(6):787-812. doi: 10.1517/17425255.2014.907274. Epub 2014 Apr 19. Review. Erratum in: Expert Opin Drug Metab Toxicol. 2014 Oct;10(10):1455. PubMed PMID: 24746233. 17: Imai C, Harazaki T, Inoue S, Mochizuki K, Goda T. Inhibition of postprandial hyperglycemia by either an insulin-dependent or -independent drug reduces the expression of genes related to inflammation in peripheral leukocytes of OLETF rats. Biosci Biotechnol Biochem. 2013;77(11):2305-8. Epub 2013 Nov 7. PubMed PMID: 24200798. 18: Mimura S, Ando T, Ishiguro K, Maeda O, Watanabe O, Ujihara M, Hirayama Y, Morise K, Maeda K, Matsushita M, Funasaka K, Nakamura M, Miyahara R, Ozaki N, Goto H. Dipeptidyl peptidase-4 inhibitor anagliptin facilitates restoration of dextran sulfate sodium-induced colitis. Scand J Gastroenterol. 2013 Oct;48(10):1152-9. doi: 10.3109/00365521.2013.832366. PubMed PMID: 24047394. 19: Hamasaki H, Yanai H. The development of angioedema in a patient with type 2 diabetes due to a novel dipeptidyl peptidase-IV inhibitor, anagliptin. Int J Cardiol. 2013 Oct 3;168(3):e106. doi: 10.1016/j.ijcard.2013.07.257. Epub 2013 Aug 2. PubMed PMID: 23972359. 20: Furuta S, Goto M, Tamura M, Yamashita S, Nakaya K, Furuta Y. The relationship between anagliptin concentration showing over 80% inhibition of plasma dipeptidyl peptidase-4 activity and its protective effect against glucagon-like peptide-1 degradation. Drug Res (Stuttg). 2014 Mar;64(3):130-5. doi: 10.1055/s-0033-1353185. Epub 2013 Aug 21. Erratum in: Drug Res (Stuttg). 2014 Aug;64(8):448. Dosage error in article text. PubMed PMID: 23965798.

View History

Amlodipine mesylate

Amlodipine mesylate